RESEARCH ARTICLE

REVISED Establishing an international laboratory network for neglected tropical diseases: Understanding existing capacity in five WHO regions [version 4; peer review: 2 approved, 1 approved with reservations]

Laura Dean¹, Janet Njelesani², Charles Mulamba¹, Russell Dacombe¹, Pamela S. Mbabazi³, Imelda Bates ¹

¹Capacity Research Unit, Liverpool School of Tropical Medicine, Liverpool, UK

²Steinhardt School of Culture, Education, and Human Development, New York University, New York, USA

³Global Working Group on Capacity Strengthening for National NTD Programmes, World Health Organization, Geneva, Switzerland

v4 First published: 14 Sep 2018, 7:1464
<https://doi.org/10.12688/f1000research.16196.1>
 Second version: 17 Oct 2018, 7:1464
<https://doi.org/10.12688/f1000research.16196.2>
 Third version: 17 Nov 2018, 7:1464
<https://doi.org/10.12688/f1000research.16196.3>
 Latest published: 02 Dec 2018, 7:1464
<https://doi.org/10.12688/f1000research.16196.4>

Abstract

Background. Limited laboratory capacity is a significant bottleneck in meeting global targets for the control and elimination of neglected tropical diseases (NTD). Laboratories are essential for providing clinical data and monitoring data about the status and changes in NTD prevalence, and for detecting early drug resistance. Currently NTD laboratory networks are informal and specialist laboratory expertise is not well publicised, making it difficult to share global expertise and provide training, supervision, and quality assurance for NTD diagnosis and research. This study aimed to identify laboratories within five World Health Organisation regions (South-East Asia, Eastern Mediterranean, Americas, Western Pacific and Europe) that provide NTD services and could be regarded as national or regional reference laboratories, and to conduct a survey to document their networks and capacity to support NTD programmes.

Methods. Potential NTD reference laboratories were identified through systematic searches, snowball sampling and key informants.

Results. Thirty-two laboratories responded to the survey. The laboratories covered 17 different NTDs and their main regional and national roles were to provide technical support and training, research, test validation and standard setting. Two thirds of the laboratories were based in academic institutions and almost half had less than 11 staff. Although greater than 90 per cent of the

Open Peer Review

Approval Status

	1	2	3
version 4			
(revision)			
02 Dec 2018			view
version 3			
(revision)			
17 Nov 2018			
version 2			
(revision)			
17 Oct 2018			
version 1			
14 Sep 2018			

1. **Charles S. Mgone** , Hubert Kairuki
Memorial University, Dar es Salaam, Tanzania
2. **Linda Oskam** , DATOS B.V., Hoofddorp,
The Netherlands
3. **Christina Zarowsky** , Chronic Diseases
Initiative for Africa (CDIA), Cape Town, South

laboratories had adequate technical skills to function as an NTD reference laboratory, almost all laboratories lacked systems for external verification that their results met international standards.

Conclusions. This study highlights that although many laboratories believed they could act as a reference laboratory, only a few had all the characteristics required to fulfil this role as they fell short in the standard and quality assurance of laboratory processes. Networks of high quality laboratories are essential for the control and elimination of disease and this study presents a critical first step in the development of such networks for NTDs.

Keywords

Neglected Tropical Diseases, Capacity Building, Laboratory Networks, Quality Assurance, Americas, Eastern Mediterranean, Europe, South-East Asia, Western Pacific

This article is included in the **Neglected Tropical Diseases** collection.

Africa

Université de Montréal, Montréal, Canada

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Laura Dean (Laura.Dean@lstmed.ac.uk)

Author roles: **Dean L:** Conceptualization, Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Njelesani J:** Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Mulamba C:** Conceptualization, Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Dacombe R:** Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Mbabazi PS:** Conceptualization, Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Bates I:** Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The study was commissioned by the World Health Organization WHO Global Working Group on Capacity Strengthening for National Neglected Tropical Diseases (NTD) Programmes [APW200811893] which reports to the NTD Strategic Technical Advisory Group.

Copyright: © 2018 Dean L *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Dean L, Njelesani J, Mulamba C *et al.* **Establishing an international laboratory network for neglected tropical diseases: Understanding existing capacity in five WHO regions [version 4; peer review: 2 approved, 1 approved with reservations]** F1000Research 2018, 7:1464 <https://doi.org/10.12688/f1000research.16196.4>

First published: 14 Sep 2018, 7:1464 <https://doi.org/10.12688/f1000research.16196.1>

REVISED Amendments from Version 3

- In the introduction, methods, results and discussion sections in the revised text we have clarified that the accreditation refers to NTD tests.
- We have stated in the introduction it is a *requirement* rather than a *function* of NTD reference laboratories is to maintain their own accreditation.
- We have flagged that the total number of staff in the laboratory were not necessarily working full-time on NTD tests.
- We have changed the number of NTDs from "20" to "17"
- We have expanded our recommendations to include that a wide-ranging stakeholder consultation process should be supplemented by in-depth studies including interviews with laboratory staff and users, and decision-makers, to understand the requirements and context in which such laboratories need to operate.

See referee reports

Introduction

Laboratories are recognised as one of the weakest elements of health systems due to chronic under-investment. Lack of investment results in poor infrastructure, inadequate numbers and skills of technical staff, insufficient and uncoordinated technical assistance, and lack of diagnostic tools appropriate for low-resource settings^{1,2}. Yet laboratory services are integral to interventions for the surveillance, control and elimination of neglected tropical diseases (NTDs). Laboratories provide clinical and monitoring data about disease prevalence and trends, and are essential for flagging up early signs of drug resistance^{1,3-6}. Appropriate management of clinical cases of NTDs depends on laboratories providing accurate diagnoses for identifying cases^{5,6}. Preventive chemotherapy interventions through mass drug administration (MDA) rely on laboratory data to make decisions regarding intervention effectiveness and for reliably documenting progress towards zero transmission⁵.

Accelerated scale-up of existing interventions is critical to reach the 2020 NTD Roadmap targets on the control and elimination of NTDs, however, lacking laboratory capacity is a critical bottleneck preventing the international NTD community from meeting targets. There needs to be enhanced laboratory ability in areas with significant NTD prevalence to provide technical and scientific support for the diagnosis, surveillance, monitoring and evaluation of national NTD programmes⁷. The World Health Organisation's (WHO) Strategic and Technical Advisory Group (STAG) for Neglected Tropical Diseases have therefore prioritised strengthening the capacity of NTD laboratories and establishing a formal NTD laboratory network which can provide a quality assurance and referral function⁸.

Globally, few laboratories specialise in NTDs. Laboratory support for NTD programmes is generally provided by parasitology laboratories within national health care systems or research institutions⁹. Most of these laboratories focus on malaria, and to a lesser extent on soil transmitted helminths (STH), with very little laboratory expertise in other NTDs¹⁰. No central register of specialist NTD laboratories exists. NTD laboratory expertise

is fragmented and un-coordinated, with no formal referral system or network to provide high level support from internationally-accredited reference laboratories for quality assurance of NTD testing. Consequentially, much laboratory data available on NTDs, that has been used to make important strategic decisions about programme implementation and transmission rates, may have been generated by laboratories working in isolation that are not enrolled in any external quality assurance scheme. The global laboratory infrastructure for NTD control programmes lags behind many other global health programmes, such as those for tuberculosis, malaria, poliomyelitis, measles and hepatitis, which successfully established a globally connected network of laboratories and systems for externally validating disease-specific laboratory data as recommended by the World Health Assembly^{11,12}.

To identify and harness existing capacity and to improve efficiency, laboratories that support national NTD programmes need to be mapped and organised into a functional international network. At the top tier, there should be internationally accredited and interlinked national reference laboratories. Each of which should head a pyramidal referral structure comprising laboratories at, for example, provincial level who support more peripheral district and primary care sites involved in front-line diagnosis and surveillance. A requirement of NTD reference laboratories is to maintain their own accreditation and service quality, and to facilitate provision of quality services by lower level laboratories through, for example, offering training on good laboratory practice and quality management systems, external quality assessment and referral testing, and monitoring performance standards through the organisation of regular proficiency testing¹.

Information about the location and expertise of laboratories with specialist NTD expertise across WHO regions is scarce and difficult to access. It is not generally known whether these laboratories meet international accreditation standards for their NTD tests or have the capacity, expertise, and networks that would enable them to operate as national or regional reference centres. Creating a database of laboratories that includes a description of what support they can provide for NTD programmes is an essential first step in the process of establishing an international and regional NTD laboratory network.

This study aimed to identify laboratories that provide NTD services and could be regarded as national or regional reference laboratories within WHO regions, and to document their capacity to support NTD programmes. It covered five of WHO's six regions since the WHO Africa region office conducted its own complementary study and the results could not be collated due to differing study methods. Our study mapped the geographical distribution and networks of these laboratories, and collated information about the skills and services they provided to support NTD programmes. Scoping the current situation provides a platform on which to design strategies to build an international network of accredited NTD reference laboratories. Such a network is essential to overcome the laboratory bottleneck which is a key barrier in accelerating intervention scale-up to meet 2020 NTD Roadmap goals⁷.

Methods

There is no existing global register of specialist NTD laboratories. This scoping study developed an unbiased and comprehensive way of identifying potential NTD reference laboratories in the five WHO regions – Americas, Eastern Mediterranean, Europe, South-East Asia and Western Pacific. As there was no pre-existing definition of an ‘NTD reference laboratory’, we extracted information from published literature^{13–17} about the laboratory characteristics needed to fulfil diagnostic, research, supervision, training, quality, and networking requirements of a national or regional reference laboratory for NTDs, and verified them with NTD control programme specialists. These characteristics were:

- able to conduct verifiable quality diagnosis in one or more NTDs
- able to support research into NTDs prevalent in their region
- able to train and mentor staff in national or tertiary level laboratories within the region
- actively networked with other national and international NTD laboratories and research institutions
- evidence of accreditation of NTD tests to international standards (e.g., ISO 15189, Good Clinical Laboratory Practice (GCLP))

Detailed information from the literature about each of these characteristics was used to design an electronic survey administered through Bristol On-line Survey (now [Online surveys](#)) to laboratories in the five WHO regions with potential to be national or regional NTD reference laboratories. Topics covered were: location and geographical coverage, NTD tests available, accreditation status, staffing, ability to provide training and technical support, and any capacity gaps the laboratory perceived they had in relation to NTDs.

To identify as many potential regional reference laboratories to include in the survey, and to avoid bias, two wide-ranging search strategies were used. Firstly, key informants were identified from international NTD programmes and research institutions and through WHO regional offices. These included WHO officers in each of the five regions, representatives of multi-lateral agencies supporting laboratory networks and centres, and NTD funders and researchers. Snowballing was used to identify further key informants.

Each key informant was asked to identify which laboratories they were aware of that could be considered an NTD reference laboratory based on our pre-defined list of characteristics. Laboratories did not have to focus exclusively on NTDs, since NTDs may be part of a larger portfolio of work but needed to have a reputation as a referral laboratory (or laboratory unit) for NTDs. 25 key informants provided contact details for 69 laboratories that they considered may be perceived as an NTD reference laboratory.

Secondly, an internet search for potential NTD reference laboratories was conducted. Countries affected by NTDs in each of the five WHO regions were identified from information on

NTD strategies and/or activities in documents on WHO regional websites^{18–23}, from country-specific information in the WHO NTD roadmap, and from individuals in the WHO Global Working Group on Capacity Strengthening for national NTD programmes. Overall 60 countries were identified as being affected by and prioritising NTDs in the five WHO regions: The Americas 17 countries, South-East Asia 11 countries, Europe 8 countries, Eastern Mediterranean 14 countries, and Western Pacific 10 countries. Potential NTD reference laboratories were identified by searching websites of national NTD programmes in NTD-affected countries, and the websites of the WHO regional offices, and by following additional links and references provided on these websites. The internet search strategy identified 98 laboratories that may potentially be NTD reference laboratories.

For each identified laboratory, contact details of laboratory heads were obtained from the websites or through key informants. Overall the combined searches yielded 167 contacts in potential reference laboratories. Each contact person was provided with information about the purpose and content of the survey by e-mail and asked to complete the survey. In order to increase response rates, the Modified Dillman approach²⁴ was used which involved fortnightly reminders about the survey for a period of five weeks between October 2013-January 2014 until the survey closed. The survey was also offered in Spanish as appropriate. Following closure of the surveys, 35 telephone calls were made to collect information from non-respondents. These focussed particularly on the European and Americas regions due to low response rates and generated one additional completed survey.

Data from the survey was entered into an excel spreadsheet and anonymised. Data was analysed to provide quantitative, descriptive information, and content analysis was conducted to identify NTD laboratories that met or were close to meeting the characteristics of a reference laboratory.

Results

Response rates and geographical coverage

Nineteen percent (n=32) of the 167 of the laboratory heads contacted responded to the survey. The majority of respondents were from the Eastern Mediterranean region (34%, n=11) ([Table 1](#)). No responses were received from the European region. The majority of laboratories (53%, n=17) provided a national level service and 25% (n=8) operated at the international level, predominantly within their own WHO region. The main regional role of surveyed laboratories was the provision of technical support (22%, n=7) and training (22%, n=7) to other laboratories though some were also involved in research, test validation and standard setting ([Table 1](#)).

Resources and capacities

Laboratories tended to be small with almost half (47 %, n=15) employing 1–10 staff and three-quarters (76%) employing 30 or less. The South-East Asia region had the highest number of staff per laboratory. The Eastern Mediterranean region had the least staff and commonly lacked quality officers, management and administrative staff. Ninety one percent (n=29) of laboratories indicated that their staff had the necessary technical

Table 1. Characteristics and distribution of potential neglected tropical disease (NTD) reference laboratories.

Main characteristics	Laboratories n=32 (%)
Laboratory location (by WHO region)	
Eastern Mediterranean	11 (34)
South-East Asia	10 (31)
Western Pacific	8 (25)
The Americas	3 (9)
Europe	0 (0)
Geographical coverage	
National	17 (53)
International	8 (25)
Sub-national	7 (22)
Regional Role	
Technical support to other laboratories	7 (22)
Providing training for other laboratories	7 (22)
Developing, validating and testing NTD methods and protocols	5 (16)
Advising on, and meeting, NTD research needs	5 (16)
Taking part in standardization on accreditation and certification	2 (6)
Other	6 (19)
Total number of staff in the laboratory*	
1–10	15 (47)
11–30	9 (29)
31–50	3 (9)
More than 50	5 (16)
Self-identified capacity gaps	
Lack of external Quality Assurance	9 (28)
Insufficient capacity to provide technical support	4 (13)
Insufficient expertise to conduct quality control of laboratory activities linked to NTDs	3 (9)
Insufficient capacity to conduct NTD diagnostics	3 (9)
Insufficient capacity to conduct NTD research	3 (9)
Insufficient capacity to support staff training	2 (6)
Inability to promote strategic plan	1 (3)
Insufficient funds	1 (3)
Insufficient human resource	1 (3)
None	5 (16)

*staff were not necessarily working full-time on NTD tests

skills to function as an NTD reference laboratory and only one laboratory strongly believed it lacked this technical capacity. Two thirds (69%, n=22) of the laboratories were based in academic institutions and felt they were strong in supporting NTD research. The majority of laboratories (78 %, n=25) identified at least one gap in their capacity, most commonly external quality assurance, which was reported as lacking by 9 (28%) laboratories. The type of capacity gaps was similar across all five regions.

NTD specialisation

The 32 laboratories covered 17 different NTDs across five WHO regions with 23 laboratories (72%) covering two or more NTDs. Most laboratories within the Eastern Mediterranean region (73%, n=8) specialised in leishmaniasis. Within the Western Pacific region, laboratories tended to focus on STH (50%, n=4) and schistosomiasis (50%, n=4). Laboratories in South-East Asia focused on STH (60%, n=6) and lymphatic filariasis (60%, n=6). Chagas disease, taeniasis, cysticercosis, echinococcosis, onchocerciasis and dengue were the only NTDs covered in the Americas region.

International standards, quality assurance for NTD testing and networks

There was variation in adherence to laboratory quality standards. Only four (13%) stated adherence to international standards such as Good Laboratory Practice, ISO 15189 and ISO 9000. 47 percent (15) of laboratories adhered to national quality standards and 40% (13) did not adhere to any. Although 47% (19) of laboratories reported a quality officer, only five (16%) participated in an external quality assurance (EQA) programme for NTD tests. Four of these were in the Eastern Mediterranean region. All five stated that less than 5% of their results within the last 3 years had been unsatisfactory. In the Western Pacific, South-East Asia and Americas regions, at least 90% (12) of laboratories did not participate in an external quality assurance scheme. Fourteen (44%) laboratories had regular interactions with international NTD networks including Drugs for Neglected Diseases Initiative, Tropical Disease Research and regional NTD elimination programmes. International conferences, regional meetings, and NTD workshops, were the predominant modes of networking reported. Despite the majority (91%) of laboratories believing they have the capacity to carry out the role of a reference laboratory, only 14% (n=3) met all the pre-determined characteristics.

Dataset 1. De-identified survey data

<http://dx.doi.org/10.5256/f1000research.16196.d217501>

Conclusions

This study marks an important step in a process towards creating the need and awareness for an international network of NTD expert laboratories. We used a systematic and wide-ranging approach to identify 32 laboratories distributed across four of five WHO regions which have potential to be regional or national reference laboratories for NTDs. Between them, these laboratories reported that they have the technical skills to provide expertise in 17 different NTDs with each laboratory focussing on NTDs that are prevalent in their region. These laboratories could form the top tier of an interlinked network of

laboratories capable of providing quality information for NTD programmes and able to act as NTD research and training centres. Half the laboratories operated at national level and a quarter at regional level and this two-level geographical focus forms a sound basis for creating national and international NTD laboratory networks.

Although over 90% of the laboratories surveyed in this study believed they could act as a reference laboratory, only 3 had all the characteristics required to fulfil this role. Almost all laboratories fell short in the area of standards and quality assurance of laboratory processes. A consistent finding was that 87% of laboratories did not adhere to international quality standards and 40% did not adhere to national quality standards. Further evidence of the paucity of quality systems is that only five of the 32 laboratories participated in an EQA programme for NTD tests; four of these were in the Eastern Mediterranean region. This means there is no independent verification that laboratory results meet international standards. Such verification is imperative in order to generate reliable results and lack of verification undermines confidence in data concerning NTD prevalence, trends and reduced drug efficacy²⁵. Unless NTD data originates from quality assured, accredited laboratories, reports about progress towards global NTD targets will lack credibility.

It is not clear why laboratories felt that they were able to act as reference laboratories even though many did not adhere to national or international quality standards and most were not enrolled in external quality schemes. This finding suggests that the importance of being able to demonstrate that test results are reliable may be under-recognised even among laboratory professionals and that this validation is not demanded by NTD programme managers and other decision makers.

Limitations

Overall, we contacted 167 laboratories and received information from 32, a third of which were located within the Eastern Mediterranean region; none were in the European region. We used a broad search strategy, so a high response rate was not anticipated since it was likely that many laboratories contacted were not involved in reference-level NTD work. However, it is possible that our search missed some relevant laboratories or that we did not identify some laboratories because contact details were incorrect, or language barriers prevented some managers from responding. The methods used to identify laboratories may have biased the results towards those that are well-known or well-publicised and self-reporting could have led to over-estimation of the capacity of laboratories. The willingness of these laboratories to act as regional reference laboratories was not assessed as part of this study.

Recommendations

The majority of laboratories covered at least two different NTDs. This diversity raises an important question about whether each laboratory should focus on one NTD or several. This will in part be dictated by existing expertise and by the burden of different NTDs in the vicinity. The most efficient use of resources may be to centralise expertise for several NTDs

within one laboratory. This would facilitate throughput of large numbers of samples and centralise the expensive, state-of-the-art diagnostic tools needed to provide high levels of diagnostic specificity and sensitivity^{26–28}. Amalgamation of laboratory services for several NTDs is complex and would need to be carefully managed to maintain rigorous systems and quality standards across a large range of services and to get buy-in from national programme managers and other laboratories²⁵.

Most of the laboratories specialising in NTDs are based in research institutions. This is an important factor to consider when planning an international NTD laboratory network since the primary goal of these laboratories is to generate research. This goal may not always be aligned with the priorities of national NTD programmes to provide routine service delivery and training. Research laboratories are characterised by short-term projects with high staff turnover and are strongly influenced by the topical interests of donors. The difference in priorities faced by research laboratories and NTD programmes means that potential tensions need to be anticipated and managed if a research laboratory is the primary provider of national or regional NTD laboratory expertise.

Although only three of the identified laboratories had all the characteristics of a reference laboratory, within each of the four WHO regions surveyed there are at least two laboratories that could be strengthened to reach international accreditation status for NTD tests and fulfil a role as a regional reference centre for NTDs. Responses from these laboratories indicated they have some experience in implementing international laboratory standards, in using advanced diagnostic tools and in providing technical support and training to other laboratories. At least some of the surveyed laboratories have the potential to be in the top global tier as regional reference laboratories once they are able to adhere to international quality standards. If they are integrated into a formal laboratory network, they will be able to, for example, share equipment, develop standardised indicators and regular monitoring protocols for laboratory performance and staff competence²⁹, and provide training, supervision and mentoring for lower tier laboratories.

This study provides preliminary information about the location and expertise of high-level laboratories specialising in NTDs. The data we collected was self-reported by laboratory personnel, so an important next step will be for additional information from European and African NTD laboratories to be incorporated, and for selected laboratories to undergo a more in-depth and independent assessment of their capacity. Criteria then need to be agreed and used to strategically select a small number of laboratories in each region which will be supported technically and financially to achieve international accreditation for NTD tests and formal recognition as regional NTD reference laboratories. These laboratories can then form foci around which to construct a global network of NTD laboratories with the longer term aim of encompassing national and sub-national laboratories within the network. A wide-ranging stakeholder consultation process, likely conducted under the stewardship of the NTD STAG which reports directly to the Director General of WHO, will be needed

to define the criteria for selecting laboratories and to define the goal and operation of the NTD laboratory network³⁰. This should be supplemented by in-depth studies including interviews with laboratory staff and users, and decision-makers, to understand the requirements and context in which such laboratories need to operate. Only when this laboratory network is operational will it be possible to have effective and rapid regional and global referral and quality assurance systems and to have confidence in the NTD test results that are essential to support NTD programme operations and research needs^{12,27}.

Data availability

Dataset 1: De-identified survey data [10.5256/f1000research.16196.d217501](https://doi.org/10.5256/f1000research.16196.d217501)³¹

Consent

Potential participants were informed about the purpose and content of the survey and could choose whether or not to complete the survey.

Grant information

The study was commissioned by the World Health Organization WHO Global Working Group on Capacity Strengthening for National Neglected Tropical Diseases (NTD) Programmes [APW200811893] which reports to the NTD Strategic Technical Advisory Group.

Supplementary material

Supplementary File 1: World Health Organization (WHO) regions survey. Includes questions and possible responses

[Click here to access the data.](#)

References

1. Nkengasong JN, Nsubuga P, Nwanyanwu O, *et al.*: **Laboratory systems and services are critical in global health: time to end the neglect?** *Am J Clin Pathol.* 2010; **134**(3): 368–373.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. **PEPFAR Conceptual Framework: Integrated Laboratory Strengthening for High Burden Diseases (Tuberculosis, HIV, and Neglected Tropical Diseases).** Geneva: Undated. (accessed 2016 Jan 20).
[Reference Source](#)
3. **Regional Strategic Plan for Neglected Tropical Diseases in the African Region 2014–2020.** Brazzaville: World Health Organisation. 2013; (accessed 2016 Jan 20).
[Reference Source](#)
4. **Schistosomiasis Progress Report 2001–2011 and Strategic Plan 2012–2020.** Geneva: World Health Organisation. 2013; (accessed 2016 Jan 20).
[Reference Source](#)
5. **Assuring Safety of Preventive Chemotherapy Interventions for the Control of Neglected Tropical Diseases.** Geneva: World Health Organisation. 2011; (accessed 2016 Jan 20).
[Reference Source](#)
6. Utzinger J, Becker SL, Knopp S, *et al.*: **Neglected tropical diseases: diagnosis, clinical management, treatment and control.** *Swiss Med Wkly.* 2012; **142**: w13727.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. **Accelerating work to overcome the Global Impact of Neglected Tropical Diseases: A road map for implementation.** Executive summary. Geneva: World Health Organisation. 2012; (accessed 2016 Jan 20).
[Reference Source](#)
8. Salle D: **Report of the Sixth meeting of the WHO Strategic and Technical Advisory Group for Neglected Tropical Disease.** Geneva 29–30 April, 2013. Geneva: World Health Organisation; 2013; (accessed 2016 Jan 20).
[Reference Source](#)
9. Richardson H, Fleming C, Palmer J, *et al.*: **An assessment of the utilization of diagnostic parasitology laboratory services in Ontario.** *Can J Infect Dis.* 1996; **7**(4): 237–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Chinery WA: **Diagnostic laboratory parasitology—a stepping stone to medical research in tropical Africa.** *J Hyg Epidemiol Microbiol Immunol.* 1992; **36**(4): 356–61.
[PubMed Abstract](#)
11. **Protocol for Assessing National Surveillance and Response Capacities for the International Health Regulations (2005).** Geneva: World Health Organisation. 2010; (accessed 2016 Jan 20).
[Reference Source](#)
12. Roush S, Baldy L: **Laboratory support for the surveillance of vaccine-preventable diseases.** In: Roush S, Baldy L, ed. *VPD Surveillance Manual.* Atlanta: Centers for Disease Control and Prevention. 2008; (accessed 2016 Jan 20).
[Reference Source](#)
13. Datema TA, Oskam L, Engelberts MF, *et al.*: **Global laboratory initiative tool for a stepwise process towards tuberculosis laboratory accreditation.** *Int J Tuberc Lung Dis.* 2012; **16**(5): 704–705.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Martin R, Barnhart S: **Global laboratory systems development: needs and approaches.** *Infect Dis Clin North Am.* 2011; **25**(3): 677–91, x.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Yao K, McKinney B, Murphy A, *et al.*: **Improving quality management systems of laboratories in developing countries: an innovative training approach to accelerate laboratory accreditation.** *Am J Clin Pathol.* 2010; **134**(3): 401–409.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Maruta T, Motebang D, Mathabo L, *et al.*: **Impact of mentorship on WHO-AFRO Strengthening Laboratory Quality Improvement Process Towards Accreditation (SLIPTA).** *Afr J Lab Med.* 2012; **1**(1): 6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. **Laboratory Quality Management System Training Toolkit.** Geneva: World Health Organisation. 2016; (accessed 2016 Jan 20).
[Reference Source](#)
18. **Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation.** Geneva: World Health Organisation. 2011; (accessed 2016 Jan 20).
[Reference Source](#)
19. Regional office for the Eastern Mediterranean: **Neglected Tropical Diseases. Country Activities.** Eastern Mediterranean: World Health Organisation. 2015; (accessed 2016 Jan 20).
[Reference Source](#)
20. **Addressing diseases of poverty: An initiative to reduce the unacceptable burden of neglected tropical diseases in the Asia Pacific region.** Western Pacific Region: World Health Organisation and Asian Development Bank. 2014; (accessed 2016 Jan 20).
[Reference Source](#)
21. **Regional Strategic Plan for Integrated Neglected Tropical Disease Control in South-East Asia Region 2012–2016.** India: World Health Organisation SEARO. 2012; (accessed 2016 Jan 20).
[Reference Source](#)
22. **Regional Action Plan for Neglected Tropical Diseases in the Western Pacific Region (2012–2016).** Philippines: World Health Organisation WPRO; 2013; (accessed 2016 Jan 20).
[Reference Source](#)
23. Salle B: **Report of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases.** WHO Headquarters 8–9 April 2014. Geneva: World Health Organisation. 2014; (accessed 2016 Jan 20).
[Reference Source](#)

24. Dillman DA: **Mail and internet surveys: The Tailored Design Method**. New York: Wiley, 2000.
[Reference Source](#)
25. Hotez P, Raff S, Fenwick A, *et al.*: **Recent progress in integrated neglected tropical disease control**. *Trends Parasitol.* 2007; **23**(11): 511–514.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Chappuis F, Stivanello E, Adams K, *et al.*: **Card agglutination test for trypanosomiasis (CATT) end-dilution titer and cerebrospinal fluid cell count as predictors of human African Trypanosomiasis (*Trypanosoma brucei gambiense*) among serologically suspected individuals in southern Sudan**. *Am J Trop Med Hyg.* 2004; **71**(3): 313–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Keiser J, Duthaler U, Utzinger J: **Update on the diagnosis and treatment of food-borne trematode infections**. *Curr Opin Infect Dis.* 2010; **23**(5): 513–520.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. van Lieshout L, Polderman AM, Deelder AM: **Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections**. *Acta Trop.* 2000; **77**(1): 69–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Peter TF, Shimada Y, Freeman RR, *et al.*: **The need for standardization in laboratory networks**. *Am J Clin Pathol.* 2009; **131**(6): 867–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Kirk CJ, Shult PA: **Developing laboratory networks: a practical guide and application**. *Public Health Rep.* 2010; **125** Suppl 2: 102–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Dean L, Njelesani J, Mulamba C, *et al.*: **Dataset 1 in: Establishing an international laboratory network for neglected tropical diseases: Understanding existing capacity in five WHO regions**. *F1000Research.* 2018.
<http://www.doi.org/10.5256/f1000research.16196.d217501>

Open Peer Review

Current Peer Review Status:

Version 4

Reviewer Report 09 May 2019

<https://doi.org/10.5256/f1000research.18921.r38348>

© 2019 Zarowsky C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Christina Zarowsky

¹ Chronic Diseases Initiative for Africa (CDIA), Cape Town, South Africa

² École de santé publique, Université de Montréal, Montréal, Canada

This is a sound and useful contribution to the identified problem of improving laboratory capacity as a key dimension of meeting global NTD control targets. The structure, methods, findings, conclusions and recommendations are clear. The responses to previous reviewers' comments are adequate, both in the text and especially in the exchanges/comments directly. The content of the manuscript stands on its own as a useful though limited contribution. However, I found the gaps and limitations at least as intriguing and important and would encourage the authors to comment a bit further on these (as in the exchanges with other reviewers), notably regarding the Africa region, the zero response from the European region, and what the implications might be of basing policy and funding decisions on the basis of evidence from this smallish sample (though on the pragmatic side, if the objective is to engage with laboratories and build a network, then there is a clear logic to engaging with the ones who responded to the survey).

I wonder also if the authors might consider adjusting the title of the manuscript. The manuscript addresses some important dimensions of understanding existing capacity, though more in the form of documenting than analysing or understanding it. But the manuscript does not really address the main title, "Establishing an international laboratory network for neglected tropical diseases". The manuscript does not convincingly show that a NETWORK is the best or an appropriate response to the current situation (as opposed to strengthening the important gaps identified by the studies within countries or institutions, for example), nor does it engage at all with the dynamics, opportunities and challenges of creating and sustaining and mobilizing networks. I do not think that the study design and content lend themselves easily to this dimension, so I would suggest that the authors clarify somewhere up front or towards the end that the findings reported here may contribute to the eventual establishment of a network, and to outline up front at least briefly how they understand networks and why (a) network may be appropriate. If they prefer to refer readers to the NTD STAG recommendations, that is fine, but the paper on its own does not make a case for or directly contribute to the process of establishing a network.

The other question that came to mind as I read the paper was how NTD reference (and other) laboratories are situated in the broader ecosystem of laboratories with disease control or public health functions in general. Another reviewer also commented on this parenthetically, but I would be interested in knowing a bit more. Is it the authors' and others' view that separate laboratories are needed (a vertical approach), or that NTDs should be integrated into other health system laboratory services (a fully integrated approach), or something in between (a diagonal approach)? Coming from the public health side of HIV, MNCH and NCD control, I am less than thrilled to envisage a parallel proliferation of separate, vertical structures on the laboratory side to what we see on the health system side. I would appreciate seeing a bit more on this, as I am a novice to the NTD laboratory world as an important domain in its own right.

There are a few typo/grammatical awkwardnesses - paragraph 2, "lacking laboratory capacity" feels a bit awkward; paragraph 4, incomplete sentence ("each of which should head a pyramidal..."), under methods I would not usually say that a study can "avoid bias" but rather "decrease, limit, etc".

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Public health, health policy and systems, global health governance.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 3

Reviewer Report 22 November 2018

<https://doi.org/10.5256/f1000research.18633.r40768>

© 2018 Oskam L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linda Oskam

DATOS B.V., Hoofddorp, The Netherlands

My remarks are in italics. A major shortcoming at the moment is that it was impossible for me to track if and where changes have been made and I have very limited time to review as I am on the verge of traveling.

If there is no clear indication in the authors' response that something has been changed I had to assume that no changes were made. If changes were made after all, please indicate where and how text was changed as is common practice for revised articles.

Points that were not satisfactory addressed after this round of changes are: 1,3,4,5,8,10,11 and 12

1. The fact that data from the European and African regions are lacking is a major weakness of the article. I would suggest that the authors try to include at least the relevant laboratories from the African region.

This work was undertaken by a separate group in the WHO AFRO region who have not agreed to share the results with us. We hope these results will be published by them.

Please indicate this more clearly in the text and also flag it as a weakness. In the article you state that it is due to a difference in methodology. If that is not the case, please indicate so.

2. The authors use a list of 25 NTDs. Which NTDs these are is unclear. WHO uses a list of 20 NTDs (https://www.who.int/neglected_diseases/diseases/en/). It would be good to indicate which list of NTDs the authors use.

We have changed the number in the article to 20 as per WHO list.

OK

3. Also: NTDs are a heterogeneous lot: parasites, viruses, bacteria, fungi. How realistic is it to assume that dedicated NTD laboratories exist? In most cases it will be one or more departments or groups within bigger laboratories.

The intention was to included laboratories that dealt with one or some of the NTDs listed rather than all. The information gathered from this exercise was to be used to form a network of these heterogeneous labs.

And what is the advantage of that? Unclear to me.

4. With regard to accreditation: the laboratories that indicate that they have international accreditation: is the NTD testing portfolio included in their scope of accreditation? Otherwise it does not count as accredited lab.

The NTD portfolio is included in their scope of accreditation.

Please indicate this in the text.

5. With regard to human resources: are the numbers in the table the total number of staff in the whole lab or the number of staff actually working on NTDs? The latter is the relevant number.

This data was not recorded.

Please indicate in the text as it is a limitation

6. Do the authors think that by identifying NTD labs through published literature they may have created a bias towards research-oriented laboratories? Many routine laboratory hardly publish their work (if at all).

We did not only use published literature to identify laboratories but also used individuals from the WHO working group on Capacity Strengthening for NTD programmes who have a good knowledge of laboratories working on NTDs. We also used grey literature from targeted internet searches, for example searching websites of national NTD programmes. We also identified and interviewed key informants from international NTD programmes and WHO regional offices.

OK

7. Introduction, paragraph 4: "The role of the NTD reference laboratories is to maintain their own accreditation..." That is not a role, but a requirement to fully function as a reference laboratory. Supporting others to implement a QMS is a role.

We have changed the wording in the article to make this clearer (i.e. from role to function).

OK

8. Methodology paragraph 5: "Overall 60 countries were identified as being affected by and prioritizing NTDs..." The WHO website (see reference under point 2) puts this number at 149. Please explain the discrepancy.

This is due to not including WHO AFRO region.

149-60 = 89 and the African Region has only 55 countries according to the African Union. Please explain the difference

9. EQA programmes: I am not surprised that not many labs participate in EQA programs as I know from experience that these are often unavailable outside the big diseases. The ISO standard provides a loophole for this in the form of interlaboratory comparisons. Did the authors identify how many labs work with interlaboratory comparisons for their NTD testing?

We did not collect this information.

OK

10. How many of the labs have direct reporting for NTDs to the national disease control programs at MoH level?

We did not collect this information.

Please indicate this somewhere in the text

11. I am afraid that a network of NTD laboratories is necessary, but will be very difficult to attain: most LMIC have a severe lack of lab staff and a severe lack of funding for their health system in general. NTDs will not be among their first 100 priorities. In many cases NTD testing will have to piggyback on other testing and make use of the leftover resources of the “big” diseases. Also, funding for NTD research is limited and haphazard. I think building a sustainable network will be an enormous challenge.

We agree that the challenges to forming laboratory networks are large and hope this article will add to the debate.

Where is this indicated in the text?

12. I think that ultimately more qualitative research with multiple stakeholders (semi-structured interviews, focus group discussions) are needed to really understand how to best design and implement a sustainable laboratory network for NTDs.

We agree that more work is required to better understand how laboratories might overcome the challenges facing them in building networks. The work presented here is a scoping study to help inform discussions about forming a network of NTD laboratories.

Where is this indicated in the text?

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reader Comment 06 Dec 2018

Susie Crossman, Liverpool School of Tropical Medicine, UK

Please find below our updated responses to your comments to accompany version 4 of the article.

1. The fact that data from the European and African regions are lacking is a major weakness of the article. I would suggest that the authors try to include at least the relevant laboratories from the African region.

We agree that the information from the African region is important missing data. At the start of the study we had extensive discussions with the WHO Africa region team inviting them to participate in this global study. However they were committed to conducting their own study using their own methods which meant that even if we were able to access their data, it would not be directly comparable with our own. At the time WHO AFRO indicated that they would publish their own data about NTD laboratories. We are therefore not able to include any information from the Africa region and we have included in the limitations section of the paper.

2. The authors use a list of 25 NTDs. Which NTDs these are is unclear. WHO uses a list of 20 NTDs (https://www.who.int/neglected_diseases/diseases/en/). It would be good to indicate which list of NTDs the authors use.

We have listed 17 (not 25) NTDs which we included in the survey in the supplementary information to the paper (https://f1000researchdata.s3.amazonaws.com/supplementary/16196/aabfd21a-825a-4ff7-a29b-f76a0c6b951b_WHO_Regions_Survey.pdf). These comprised the WHO-designated NTDs at the time the survey was designed. It was only later, in 2017, that 3 additional diseases were added to the WHO list (chromoblastomycosis and other deep mycoses, scabies and other ectoparasites, and snakebite envenoming)

3. NTDs are a heterogeneous lot: parasites, viruses, bacteria, fungi. How realistic is it to assume that dedicated NTD laboratories exist? In most cases it will be one or more departments or groups within bigger laboratories.

We agree with the reviewer that we would not necessarily expect to identify many laboratories dedicated to NTDs and have stated this in the second paragraph of the introduction ('Globally, few laboratories specialise in NTDs. Laboratory support for NTD programmes is generally provided by parasitology laboratories within national health care systems or research institutions'). As the reviewer correctly anticipated, we did in fact find that NTD laboratory work was often carried out within larger laboratories including within academic institutions, and we had already mentioned this in the text (for example, in the results section of the abstract).

4. With regard to accreditation: the laboratories that indicate that they have international accreditation: is the NTD testing portfolio included in their scope of accreditation? Otherwise it does not count as accredited lab

Yes the accreditation refers to NTD tests and we have clarified this in the introduction, methods, results and discussion sections in the revised text

5. With regard to human resources: are the numbers in the table the total number of staff in the whole lab or the number of staff actually working on NTDs? The latter is the relevant number.

We agree that ideally we would have liked to know how many staff were dedicated to working on NTDs. However the majority of laboratories were part of a larger organisation (see response to comment 3) and it is likely that the staff in the laboratories were working on non-NTD tests for at least part of the time. We did not ask respondents to estimate how much time was spent working specifically on NTD tests as we suspected that this type of retrospective data would not be robust enough to be meaningful. This is something that could be explored in future studies. We have added a footnote to the table to explain that the staff numbers do not necessarily refer to those only working on NTD tests.

6. Do the authors think that by identifying NTD labs through published literature they may have created a bias towards research-oriented laboratories? Many routine laboratory hardly publish their work (if at all).

We do agree with the reviewer that bias could have been introduced if we had limited our search to only laboratories that published in academic literature. However we recognised this risk in the study design and opted not to use academic publications as a means of identifying potential laboratories to include in the study. Instead we used two wide-ranging search strategies involving a) information about NTD laboratories obtained from key informants (identified from, for example, international NTD programmes and WHO regional offices) and b) identification of potential laboratories from an internet search of websites for documents on NTDs that may contain information about laboratories. Details are already provided in the methods section of the paper.

7. Introduction, paragraph 4: "The role of the NTD reference laboratories is to maintain their own accreditation..." That is not a role, but a requirement to fully function as a reference laboratory. Supporting others to implement a QMS is a role.

We are grateful to the reviewer for this clarification and have adjusted the text accordingly.

8. Methodology paragraph 5: "Overall 60 countries were identified as being affected by and prioritizing NTDs..." The WHO website (see reference under point 2) puts this number at 149. Please explain the discrepancy..

As explained in the paper, and under comment 1 above, we were not able to include data from the Africa region so the number of countries was 60 as we excluded those in the Africa region

9. EQA programmes: I am not surprised that not many labs participate in EQA programs as I know from experience that these are often unavailable outside the big diseases. The ISO standard provides a loophole for this in the form of interlaboratory comparisons. Did the authors identify how many labs work with interlaboratory comparisons for their NTD testing?

We did not collect this information

10. How many of the labs have direct reporting for NTDs to the national disease control programs at MoH level?

We did not collect this information but would hope that these additional in-depth details, which will be essential for establishing a functional NTD laboratory network, will be collected in a subsequent study

11. I am afraid that a network of NTD laboratories is necessary, but will be very difficult to attain: most LMIC have a severe lack of lab staff and a severe lack of funding for their health system in general. NTDs will not be among their first 100 priorities. In many cases NTD testing will have to piggyback on other testing and make use of the leftover resources of the "big" diseases. Also, funding for NTD research is limited and haphazard. I think building a sustainable network will be an enormous challenge.

We agree that establishing a sustainable network of NTD laboratories is an enormous challenge but we are encouraged by the fact that WHO was closely engaged in our study and is firmly committed to the global NTD 'roadmap' strategy. Since this study was conducted WHO have reaffirmed their commitment to working towards achieving this goal stating that *"The next four years will be crucial in achieving the 2020 targets as we continue to work to integrate interventions into the broader health system and development agenda so that no one is left behind."*

http://www.who.int/neglected_diseases/news/WHO_Roadmap_five_years_of_collaboration/en/

12. I think that ultimately more qualitative research with multiple stakeholders (semi-structured interviews, focus group discussions) are needed to really understand how to best design and implement a sustainable laboratory network for NTDs.

This study was the first step on the road towards establishing a global NTD laboratory network and we agree that much more information is needed, including through working closely with a range of stakeholders, before this goal can be achieved. We have added an additional sentence in the conclusion to emphasis this point.

Competing Interests: No competing interests were disclosed.

Version 2

Reviewer Report 01 November 2018

<https://doi.org/10.5256/f1000research.18267.r39763>

© 2018 Oskam L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linda Oskam

DATOS B.V., Hoofddorp, The Netherlands

The manuscript makes a first inventory of potential NTD reference laboratories. As indicated by the first referee, it highlights the lack of NTD networking capacity. This is not unexpected in the view of this being NEGLECTED tropical disease.

A number of immediate questions that the authors in my opinion need to address are:

1. The fact that data from the European and African regions are lacking is a major weakness of the article. I would suggest that the authors try to include at least the relevant laboratories from the African region.
2. The authors use a list of 25 NTDs. Which NTDs these are is unclear. WHO uses a list of 20 NTDs (https://www.who.int/neglected_diseases/diseases/en/). It would be good to indicate which list of NTDs the authors use.
3. Also: NTDs are a heterogeneous lot: parasites, viruses, bacteria, fungi. How realistic is it to assume that dedicated NTD laboratories exist? In most cases it will be one or more departments or groups within bigger laboratories.
4. With regard to accreditation: the laboratories that indicate that they have international accreditation: is the NTD testing portfolio included in their scope of accreditation? Otherwise it does not count as accredited lab.
5. With regard to human resources: are the numbers in the table the total number of staff in the whole lab or the number of staff actually working on NTDs? The latter is the relevant number.
6. Do the authors think that by identifying NTD labs through published literature they may have created a bias towards research-oriented laboratories? Many routine laboratory hardly publish their work (if at all).
7. Introduction, paragraph 4: "The role of the NTD reference laboratories is to maintain their own accreditation..." That is not a role, but a requirement to fully function as a reference laboratory. Supporting others to implement a QMS is a role.
8. Methodology paragraph 5: "Overall 60 countries were identified as being affected by and prioritizing NTDs..." The WHO website (see reference under point 2) puts this number at 149. Please explain the discrepancy.
9. EQA programmes: I am not surprised that not many labs participate in EQA programs as I know from experience that these are often unavailable outside the big diseases. The ISO standard provides a loophole for this in the form of interlaboratory comparisons. Did the authors identify how many labs work with interlaboratory comparisons for their NTD testing?

10. How many of the labs have direct reporting for NTDs to the national disease control programs at MoH level?
11. I am afraid that a network of NTD laboratories is necessary, but will be very difficult to attain: most LMIC have a severe lack of lab staff and a severe lack of funding for their health system in general. NTDs will not be among their first 100 priorities. In many cases NTD testing will have to piggyback on other testing and make use of the leftover resources of the "big" diseases.
Also, funding for NTD research is limited and haphazard. I think building a sustainable network will be an enormous challenge.
12. I think that ultimately more qualitative research with multiple stakeholders (semi-structured interviews, focus group discussions) are needed to really understand how to best design and implement a sustainable laboratory network for NTDs.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: laboratory system strengthening; laboratory quality management; laboratory policy and planning

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reader Comment 09 Nov 2018

Susie Crossman, Liverpool School of Tropical Medicine, UK

In response to the referee report questions:

1. The fact that data from the European and African regions are lacking is a major weakness

of the article. I would suggest that the authors try to include at least the relevant laboratories from the African region.

This work was undertaken by a separate group in the WHO AFRO region who have not agreed to share the results with us. We hope these results will be published by them.

2. The authors use a list of 25 NTDs. Which NTDs these are is unclear. WHO uses a list of 20 NTDs (https://www.who.int/neglected_diseases/diseases/en/). It would be good to indicate which list of NTDs the authors use.

We have changed the number in the article to 20 as per WHO list.

3. Also: NTDs are a heterogeneous lot: parasites, viruses, bacteria, fungi. How realistic is it to assume that dedicated NTD laboratories exist? In most cases it will be one or more departments or groups within bigger laboratories.

The intention was to included laboratories that dealt with one or some of the NTDs listed rather than all. The information gathered from this exercise was to be used to form a network of these heterogeneous labs.

4. With regard to accreditation: the laboratories that indicate that they have international accreditation: is the NTD testing portfolio included in their scope of accreditation? Otherwise it does not count as accredited lab.

The NTD portfolio is included in their scope of accreditation.

5. With regard to human resources: are the numbers in the table the total number of staff in the whole lab or the number of staff actually working on NTDs? The latter is the relevant number.

This data was not recorded.

6. Do the authors think that by identifying NTD labs through published literature they may have created a bias towards research-oriented laboratories? Many routine laboratory hardly publish their work (if at all).

We did not only use published literature to identify laboratories but also used individuals from the WHO working group on Capacity Strengthening for NTD programmes who have a good knowledge of laboratories working on NTDs. We also used grey literature from targeted internet searches, for example searching websites of national NTD programmes. We also identified and interviewed key informants from international NTD programmes and WHO regional offices.

7. Introduction, paragraph 4: "The role of the NTD reference laboratories is to maintain their own accreditation..." That is not a role, but a requirement to fully function as a reference laboratory. Supporting others to implement a QMS is a role.

We have changed the wording in the article to make this clearer (i.e. from role to function).

8. Methodology paragraph 5: "Overall 60 countries were identified as being affected by and prioritizing NTDs..." The WHO website (see reference under point 2) puts this number at 149. Please explain the discrepancy.

This is due to not including WHO AFRO region.

9. EQA programmes: I am not surprised that not many labs participate in EQA programs as I know from experience that these are often unavailable outside the big diseases. The ISO standard provides a loophole for this in the form of interlaboratory comparisons. Did the authors identify how many labs work with interlaboratory comparisons for their NTD testing?

We did not collect this information.

10. How many of the labs have direct reporting for NTDs to the national disease control programs at MoH level?

We did not collect this information.

11. I am afraid that a network of NTD laboratories is necessary, but will be very difficult to attain: most LMIC have a severe lack of lab staff and a severe lack of funding for their health system in general. NTDs will not be among their first 100 priorities. In many cases NTD testing will have to piggyback on other testing and make use of the leftover resources of the "big" diseases.

Also, funding for NTD research is limited and haphazard. I think building a sustainable network will be an enormous challenge.

We agree that the challenges to forming laboratory networks are large and hope this article will add to the debate.

12. I think that ultimately more qualitative research with multiple stakeholders (semi-structured interviews, focus group discussions) are needed to really understand how to best design and implement a sustainable laboratory network for NTDs.

We agree that more work is required to better understand how laboratories might overcome the challenges facing them in building networks. The work presented here is a scoping study to help inform discussions about forming a network of NTD laboratories.

Competing Interests: No competing interests were disclosed.

Version 1

Reviewer Report 10 October 2018

<https://doi.org/10.5256/f1000research.17685.r38347>

© 2018 Mgone C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Charles S. Mgone

Hubert Kairuki Memorial University, Dar es Salaam, Tanzania

The manuscript highlights the lack of international, regional and national capacity for reference laboratories and networks for neglected tropical disease diagnosis, research and training. This includes lack of hierarchical referral system that allows escalation of problem solving based on the nature of their complexity and offers supervision and quality assurance along the chain. The paper highlights these problems very well. The data collection was based on laboratory personnel self-reporting after the laboratories were identified by informants and web searching; both inherent with bias. The identification methods used are likely to select well known or well advertised centres while self-reporting is likely to be associated with higher claims of excellence that is real. The lack of information from African and European regions is very glaring and needs to be rectified. Informed willingness of these centres to work as regional reference laboratories needs to be assessed, especially after the centres having been made aware of the terms of reference.

References

1. Dean L, Njelesani J, Mulamba C, Dacombe R, et al.: Establishing an international laboratory network for neglected tropical diseases: Understanding existing capacity in five WHO regions. *F1000Research*. 2018; 7. [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Diseases of poverty, capacity building

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reader Comment 16 Oct 2018

Susie Crossman, Liverpool School of Tropical Medicine, UK

We are grateful to Prof Mgone for his thoughtful review of our paper. We agree that the way that we selected the laboratories and the self-reporting of laboratory capacity could have biased the results towards more well-known laboratories and over-estimation of capacity. We have therefore expanded the limitations section of the paper to include a statement to this effect. We agree that there is a glaring lack of information from the African and European regions and in the discussion section we had already emphasized the need to rectify this.

Competing Interests: No competing interests were disclosed.

Comments on this article

Version 4

Reader Comment 06 Dec 2018

Susie Crossman, Liverpool School of Tropical Medicine, UK

Please find below our updated responses to your comments to accompany version 4 of the article.

1. The fact that data from the European and African regions are lacking is a major weakness of the article. I would suggest that the authors try to include at least the relevant laboratories from the African region.

We agree that the information from the African region is important missing data. At the start of the study we had extensive discussions with the WHO Africa region team inviting them to participate in this global study. However they were committed to conducting their own study using their own methods which meant that even if we were able to access their data, it would not be directly comparable with our own. At the time WHO AFRO indicated that they would publish their own data about NTD laboratories. We are therefore not able to include any information from the Africa region and we have included in the limitations section of the paper.

2. The authors use a list of 25 NTDs. Which NTDs these are is unclear. WHO uses a list of 20 NTDs (https://www.who.int/neglected_diseases/diseases/en/). It would be good to indicate which list of NTDs the authors use.

We have listed 17 (not 25) NTDs which we included in the survey in the supplementary information to the paper (https://f1000researchdata.s3.amazonaws.com/supplementary/16196/aabfd21a-825a-4ff7-a29b-f76a0c6b951b_WHO_Regions_Survey.pdf). These comprised the WHO-designated NTDs at the time the survey was designed. It was only later, in 2017, that 3 additional diseases were added to the WHO list (chromoblastomycosis and other deep mycoses, scabies and other ectoparasites, and snakebite envenoming)

3. NTDs are a heterogeneous lot: parasites, viruses, bacteria, fungi. How realistic is it to assume that dedicated NTD laboratories exist? In most cases it will be one or more departments or groups within bigger laboratories.

We agree with the reviewer that we would not necessarily expect to identify many laboratories dedicated to NTDs and have stated this in the second paragraph of the introduction ('Globally, few laboratories specialise in NTDs. Laboratory support for NTD programmes is generally provided by parasitology laboratories within national health care systems or research institutions '). As the reviewer correctly anticipated, we did in fact find that NTD laboratory work was often carried out within larger laboratories including within academic institutions, and we had already mentioned this in the text (for example, in the results section of the abstract).

4. With regard to accreditation: the laboratories that indicate that they have international accreditation: is the NTD testing portfolio included in their scope of accreditation? Otherwise it does not count as accredited lab

Yes the accreditation refers to NTD tests and we have clarified this in the introduction, methods, results and discussion sections in the revised text

5. With regard to human resources: are the numbers in the table the total number of staff in the whole lab or the number of staff actually working on NTDs? The latter is the relevant number.

We agree that ideally we would have liked to know how many staff were dedicated to working on NTDs. However the majority of laboratories were part of a larger organisation (see response to comment 3) and it is likely that the staff in the laboratories were working on non-NTD tests for at least part of the time. We did not ask respondents to estimate how much time was spent working specifically on NTD tests as we suspected that this type of retrospective data would not be robust enough to be meaningful. This is something that could be explored in future studies. We have added a footnote to the table to explain that the staff numbers do not necessarily refer to those only working on NTD tests.

6. Do the authors think that by identifying NTD labs through published literature they may have created a bias towards research-oriented laboratories? Many routine laboratory hardly publish their work (if at all).

We do agree with the reviewer that bias could have been introduced if we had limited our search to only laboratories that published in academic literature. However we recognised this risk in the study design and opted not to use academic publications as a means of identifying potential laboratories to include in the study. Instead we used two wide-ranging search strategies involving a) information about NTD laboratories obtained from key informants (identified from, for example, international NTD programmes and WHO regional offices) and b) identification of potential laboratories from an internet search of websites for documents on NTDs that may contain information about laboratories. Details are already provided in the methods section of the paper.

7. Introduction, paragraph 4: "The role of the NTD reference laboratories is to maintain their own accreditation..." That is not a role, but a requirement to fully function as a reference laboratory. Supporting others to implement a QMS is a role.

We are grateful to the reviewer for this clarification and have adjusted the text accordingly.

8. Methodology paragraph 5: "Overall 60 countries were identified as being affected by and prioritizing NTDs..." The WHO website (see reference under point 2) puts this number at 149. Please explain the discrepancy..

As explained in the paper, and under comment 1 above, we were not able to include data from the Africa region so the number of countries was 60 as we excluded those in the Africa region

9. EQA programmes: I am not surprised that not many labs participate in EQA programs as I know from experience that these are often unavailable outside the big diseases. The ISO standard provides a loophole for this in the form of interlaboratory comparisons. Did the authors identify how many labs work with interlaboratory comparisons for their NTD testing?

We did not collect this information

10. How many of the labs have direct reporting for NTDs to the national disease control programs at MoH level?

We did not collect this information but would hope that these additional in-depth details, which will be essential for establishing a functional NTD laboratory network, will be collected in a subsequent study

11. I am afraid that a network of NTD laboratories is necessary, but will be very difficult to attain: most LMIC have a severe lack of lab staff and a severe lack of funding for their health system in general. NTDs will not be among their first 100 priorities. In many cases NTD testing will have to piggyback on other testing and make use of the leftover resources of the "big" diseases. Also, funding for NTD research is limited and haphazard. I think building a sustainable network will be an enormous challenge.

We agree that establishing a sustainable network of NTD laboratories is an enormous challenge but we are encouraged by the fact that WHO was closely engaged in our study and is firmly committed to the global NTD 'roadmap' strategy. Since this study was conducted WHO have reaffirmed their commitment to working towards achieving this goal stating that *"The next four years will be crucial in achieving the 2020 targets as we continue to work to integrate interventions into the broader health system and development agenda so that no one is left behind."*

http://www.who.int/neglected_diseases/news/WHO_Roadmap_five_years_of_collaboration/en/

12. I think that ultimately more qualitative research with multiple stakeholders (semi-structured

interviews, focus group discussions) are needed to really understand how to best design and implement a sustainable laboratory network for NTDs.

This study was the first step on the road towards establishing a global NTD laboratory network and we agree that much more information is needed, including through working closely with a range of stakeholders, before this goal can be achieved. We have added an additional sentence in the conclusion to emphasis this point.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research